Helicobacter pylori Infections

Full Text Article

Nitazoxanide as Salvage Treatment for Refractory Helicobacter pylori Infections

Received Date: October 30, 2021 Accepted Date: November 30, 2021 Published Date: December 02, 2021

doi: 10.17303/jaid.2021.8.203

Citation:José A Girón (2021) Nitazoxanide as Salvage Treatment for Refractory Helicobacter pylori Infections. J HIV AIDS Infect Dis 8: 1-7.

Background:Increasing resistance of Helicobacter pylori to metronidazole and clarithromycin has resulted in greater failure rates to standard treatments. For this reason, a salvage treatment becomes necessary. In this study, we report our findings with different regimens containing nitazoxanide, an antiprotozoal agent, in the treatment of refractory H. pylori infections.

Methods:Patients were treated consecutively and had to meet the following criteria: 1) proven symptomatic H. pylori gastritis via a stool antigen test or gastric biopsy and 2) failure of at least one course of treatment with a standard regimen. The sample size totaled twenty-five patients with thirty treatment episodes utilizing ten different nitazoxanide-containing regimens. A successful treatment was defined as a negative stool antigen test performed at least four weeks post-treatment.

Results:Overall, the eradication rate for all nitazoxanide-containing treatment regimens was 70%. Of note, the most frequently prescribed regimen, which consisted of nitazoxanide 500 mg twice per day, rifabutin 150 mg twice per day, omeprazole 20 mg twice per day, and one tablespoon (15 cc) of bismuth subsalicylate three times per day, had a 91% success rate.

Conclusions:For refractory H. pylori infections, we recommend a treatment regimen consisting of nitazoxanide 500 mg twice per day, rifabutin 150 mg twice per day, omeprazole 20 mg twice per day, and one tablespoon of bismuth subsalicylate three times per day for eight to ten days. Further evaluation of nitazoxanide-containing treatment regimens is warranted.

Keywords:Helicobacter pylori; Antibiotic Resistance; Nitazoxanide; Rifabutin

Marshall and Warren first reported that Helicobacter pylori caused gastric and duodenal ulcers in 1982 [1]. H. pylori has been classified as a Class I carcinogen by the World Health Organization’s (WHO) International Agency for Research on Cancer due to its strong association with the development of gastric adenocarcinoma and gastric-associated lymphoid tissue lymphoma [2]. Up to 95% of gastric cancers are attributed to H. pylori infections [3]. H. pylori is the most common chronic bacterial infection worldwide, with prevalence ranging between 85 to 95 percent in developing countries and between 30 to 50 percent in developed countries [4-6].

The recommended treatment for H. pylori infections consists of a proton pump inhibitor, clarithromycin, and amoxicillin or metronidazole for fourteen days in areas where H. pylori resistance to clarithromycin or metronidazole is less than fifteen percent and in patients who have not had previous macrolide exposure [7]. A quadruple therapy with bismuth subsalicylate, a proton pump inhibitor, tetracycline, and metronidazole for ten to fourteen days is recommended for patients with a previous macrolide exposure, an allergy to penicillin, or where clarithromycin resistance exceeds fifteen percent [7]. If initial treatment fails, the American College of Gastroenterologists recommends that previously used antibiotics be avoided. Salvage treatments include bismuth subsalicylate quadruple therapy and levofloxacin triple therapy for fourteen days [7].

Resistance to standard treatments has increased in recent years. The WHO designated H. pylori a high priority subject for antibiotic resistance research and development in 2018 for this reason [8]. A meta-analysis involving 178 studies from 65 countries showed that primary resistance rates for clarithromycin, metronidazole, and levofloxacin were 15% or higher in nearly all regions investigated [8].

The rising prevalence of resistant H. pylori infections has been associated with failure of first line regimens. We define a refractory H. pylori infection as one which has failed to respond to one or more courses of standard treatment. Several studies have shown promising results for nitazoxanide in the treatment of H. pylori infections [9]. Nitazoxanide is currently approved by the U.S. Food and Drug Administration (FDA) for use to treat Cryptosporidium and Giardia infections [10]. In our practice we have evaluated patients with refractory H. pylori infections referred for management and treatment. A meta-analysis of ten studies that utilized a nitazoxanide-based treatment regimen for H. pylori found a cure rate of 80% or more in eight of the ten studies [9]. Based on these reports, we employed a variety of nitazoxanide-containing regimens to treat patients who had failed prior therapeutic trials.

We report our experience with nitazoxanide containing regimens in a group of patients with refractory H. pylori infections.

We collected all patients who were referred for refractory symptomatic H. pylori infection between 2015 and 2021. The patients met the following criteria: (1) proven symptomatic H. pylori gastritis or ulcer diagnosed with a stool antigen test (enzyme immunoassay via Quest or LabCorp) or gastric biopsy; (2) failure of at least one course of treatment with a standard regimen. The stool antigen test utilized had an overall sensitivity and specificity of greater than 95% [11]. The sample size totaled twenty-five patients, sixteen females and nine males with an average age of 60.4. (Table 1). Patients were treated using ten different nitazoxanide-containing treatment regimens for a total of thirty treatment episodes (Table 2). Some patients were given successive treatments with nitazoxanide, however in each case the supporting antibiotics were changed. All patients had a complete evaluation (history, physical, laboratory testing). Information collected from chart reviews included medical histories, date of evaluation, H. pylori test result, number and type of prior treatments, symptoms prior to treatment, type of nitazoxanide-containing salvage treatment prescribed, length of treatment measured in days, treatment outcome, and symptoms post-treatment. Four patients reported potential adverse effects: one instance of bloating, two instances of diarrhea, and one instance of nausea. We defined a successful treatment outcome as a negative H. pylori stool antigen test performed at least four weeks after the treatment regimen was completed. We report the percentage cure rates for the usage of nitazoxanide-containing regimens and for the individual treatment regimens themselves.

This study included twenty-five patients and a total of thirty treatment episodes. The average prior number of treatments was three (Table 5), with medications such as clarithromycin, levofloxacin, metronidazole, and amoxicillin (Table 3). The range in the length of salvage treatments was five to twelve days (Table 5). The most commonly reported symptom amongst the patients prior to treatment was abdominal pain. Overall, the eradication rate for nitazoxanide-containing treatment regimens was 70%, with twenty-one of the thirty treatment episodes resulting in H. pylori eradication (Table 4). Of those twenty-one

successful treatment episodes, seventeen of the patients reported complete symptom resolution. The most commonly reported symptom amongst the remaining patients was abdominal pain. Upon further evaluation of the individual treatment regimens, it was noted that the regimens with the highest eradication rates, regimens 5, 6, 7, 8, 9, and 10, had a combined eradication rate of 85%, with seventeen out of the twenty treatment episodes classified as successful (Table 4). Additionally, the most frequently prescribed regimen, Treatment 6, which consisted of rifabutin 150 mg twice per day, nitazoxanide 500 mg twice per day, omeprazole 20 mg twice per day, and one tablespoon (15 cc) of bismuth subsalicylate three times per day, had a 91% success rate (Table 5).

Over time, increasing rates of resistance have been reported for clarithromycin, metronidazole, and levofloxacin. A retrospective study in the Netherlands showed significant increases in resistances to clarithromycin (9.8 to 18.1%), metronidazole (20.7 to 23.2%), and ampicillin (6.3 to 10%) over a period of ten years [12]. An analysis of primary antibiotic resistance in Asian-Pacific regions demonstrated resistance rates of 17% for clarithromycin, 44% for metronidazole, and 18% for levofloxacin [13]. Moreover, other studies indicate that even previous antibiotic use in general increases the risk of harboring resistant H. pylori strains [14-15]. Thus, it is imperative that salvage regimens be developed.

Nitazoxanide-containing regimens have been shown to be comparable or superior to standard regimens [16]. The regimens that demonstrated the highest eradication rates were regimens that contained nitazoxanide plus a proton pump inhibitor and one or two antibiotics [9]. Furthermore, nitazoxanide has shown promise in patients who have failed previous treatment. An Egyptian study demonstrated an eradication rate of 83% in patients prescribed a quadruple therapy of nitazoxanide, levofloxacin, omeprazole, and doxycycline for fourteen days [17].

We sought to evaluate the efficacy of nitazoxanide-containing regimens for the treatment of refractory Helicobacter pylori infections. We defined refractory H. pylori infections as those which had failed one or more treatments with standard regimens. The overall cure rate for the various treatment combinations was 70% (Table 4). One treatment regimen had a remarkable success rate of 91% (Table 5). This treatment regimen consisted of nitazoxanide 500 mg twice per day, rifabutin 150 mg twice per day, omeprazole 20 mg twice per day, and one tablespoon (15 cc) of bismuth subsalicylate three times per day. The average length of treatment was nine days, with a range of eight to ten days (Table 4).

A study by Hoffman and colleagues in 2007 proposed that the mechanism for the action of nitazoxanide on H. pylori is through the noncompetitive inhibition of bacterial pyruvate: ferredoxin/flavodoxin oxidoreductases, which may bypass mutation-based drug resistance [18].

There are a few limitations of this study that must be considered when evaluating the results. We were only able to include twenty-five patients, which may affect the reliability of the results and increase the possibility of a type II statistical error. In addition, we did not have the ability to test antibiotic susceptibility in our patients, as gastroscopy was not repeated in the treatment process. A distinct advantage to the study is that we achieved symptomatic and clinical cures with a regimen lasting between eight to ten days. Other studies have achieved cures with treatments lasting fourteen days. Shorter treatment regimens are more advantageous because they decrease overall antibiotic exposure, lessen the risk of adverse effects, and reduce the risk of producing resistant organisms [19].

Our findings indicate that nitazoxanide may be used to treat refractory H. pylori infections. A treatment regimen of nitazoxanide 500 mg twice per day, rifabutin 150 mg twice per day, omeprazole 20 mg twice per day, and one tablespoon (15 cc) of bismuth subsalicylate three times per day for eight to ten days results in successful eradication of H. pylori infections. We believe further evaluation of nitazoxanide-containing treatment regimens is warranted, especially the nitazoxanide-rifabutin regimen in comparison to currently-recommended standard salvage regimens.

Since the completion of this manuscript, four more patients have been successfully treated with the regimen of nitazoxanide 500 mg twice per day, rifabutin 150 mg twice per day, omeprazole 20 mg twice per day, and one tablespoon (15 cc) of bismuth subsalicylate three times per day for eight days with no reported adverse effects. This raises the cure rate to 93%. Additionally, the regimens with the highest eradication rates, regimens 5, 6, 7, 8, 9, and 10, now have a combined eradication rate of 88%.

Thank you to the staff at Sunshine Specialty Care in Orlando, Florida for their assistance on this project.

  1. Marshall BJ, Warren JR (1984) Unidentified Curved Bacilli In the Stomach of Patients with Gastritis And Peptic Ulceration. Lancet 323: 1311-15.
  2. Anwar W, Armstrong BK, Correa P (1994) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Schistosomes, Liver Flukes, And Helicobacter Pylori. Vol 61. UK: World Health Organization 1994: 221.
  3. Shiotani A, Cen P, Graham DY (2013) Eradication of gastric cancer is now both possible and practical. Semin Cancer Biol 6: 492-501.
  4. Khoder G, Muhammad JS, Mahmoud I, Soliman SSM, Burucoa C (2019) Prevalence of Helicobacter pylori and Its Associated Factors among Healthy Asymptomatic Residents in the United Arab Emirates. Pathogens 8: 44.
  5. Cover TL, Blaser MJ (2009) Helicobacter pylori in health and disease. Gastroenterology 136: 1863-73.
  6. Hunt RH, Xiao SD, Megraud F (2011) Helicobacter pylori in developing countries. World Gastroenterology Organisation Guideline. J Gastrointestin Liver Dis 20: 299-304.
  7. Chey WD, Leontiadis GI, Howden CW, Moss SF (2017) ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastreoenterol 112: 212-39.
  8. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E (2018) Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-Analysis in World Health Organization Regions. Gastroenterology, 2018; 155: 1372-82.e17.
  9. Lee S, Sneed GT, Brown JN (2020) Treatment of Helicobacter pylori with nitazoxanide-containing regimens: a systematic review. Infect Dis (Lond) 52: 381-90.
  10. U.S. Food & Drug Administration (2020) First Generic Drug Approvals.
  11. Best LM, Takwoingi Y, Siddique S (2018) Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev 3: CD012080.
  12. Ruiter R, Wunderink HF, Veenendaal RA, Visser LG, de Boer MGJ (2017) Helicobacter pylori resistance in the Netherlands: a growing problem? Neth J Med 75: 394-98.
  13. Kuo YT, Liou JM, El-Omar EM (2017) Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2: 707-15.
  14. Megraud F, Coenen S, Versporten A (2013) Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62: 34-42.
  15. Aldana LP, Kato M, Nakagawa S (2002) The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 7: 306-9.
  16. Shehata MA, Talaat R, Soliman S, Elmesseri H, Soliman S, et al. (2017) Randomized controlled study of a novel triple nitazoxanide (NTZ) containing therapeutic regimen versus the traditional regimen for eradication of Helicobacter pylori infection. Helicobacter 22: e312395.
  17. Abd-Elsalam S, Kobtan A, El-Kalla F (2016) A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. Medicine (Baltimore) 95: e3879.
  18. Hoffman PS, Sisson G, Croxen MA (2007) Antiparasitic drug nitazoxanide inhibits the pyruvate oxoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob Agents Chemother 51: 868-76.
  19. Lee RA, Centor RM, Humphrey LL, Jokela JA, Andrews R, et al. (2021) Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians. Ann Intern Med 6: 822-27.
CommentsTable 1 CommentsTable 2 CommentsTable 3 CommentsTable 4 CommentsTable 5